Romidepsin: A histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma;Romidepsina: Un inhibidor de la histona deacetilasa para el tratamiento del linfoma cutáneo de células T refractario

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1340-1348

  Kim, Miryoung ^a   Thompson, Lisa A ^b   Wenger, Sarah D ^b   O'Bryant, Cindy L ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cutaneous T cell lymphoma; Depepsitide (FK228); Histone deacety lase inhibitor; Romidepsin

Indexed keywords

ROMIDEPSIN; WARFARIN;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG LABELING; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ELECTROCARDIOGRAM; FATIGUE; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HUMAN; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

DEPSIPEPTIDES; DRUG INTERACTIONS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; TREATMENT OUTCOME;

EID: 84867836211     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R036     Document Type: Article

References (54)

1. Zinzani PL, Ferreri AJ, Cerroni L. Mycosis fungoides. Crit Rev Oncol Hematol 2008;65:172-82.
2. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-9.
3. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Derma-tol 2003;139:857-66.
4. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:5064-73.
5. Russell-Jones R, Whittaker S. Sézary syndrome: diagnostic criteria and therapeutic options. Semin Cutan Med Surg 2000;19:100-8.
6. Poligone B, Lin J, Chung C. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid 2011;6:1-12.
7. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R, Dermatologists BAo, Group UKCL. Joint British Association of Dermatologists and UK. Cutaneous Lymphoma Group guidelines for the management of pri-mary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095-107.
8. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recom-mendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-30.
9. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and criti-cal review of treatment options. J Am Acad Dermatol 1990;22:381-401.
10. Willemze R, Dreyling M, Group EGW. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v177-80.
11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-Hodgkin's lymphoma. V.4.2011. www.nccn.org (accessed 2011 Dec 5).
12. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treat-ment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009;21:131-7.
13. Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syn-drome). Ann Intern Med 1994;121:592-602.
14. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-7.
15. Horwitz SM. The emerging role of histone deacetylase inhibitors in treat-ing T-cell lymphomas. Curr Hematol Malig Rep 2011;6:67-72.
16. Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase in-hibitor for cancer. Expert Opin Investig Drugs 2011;20:1151-8.
17. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lym-phoma. Curr Opin Oncol 2010;22:431-6.
18. Yang LP. Romidepsin: in the treatment of T-cell lymphoma. Drugs 2011; 71:1469-80.
19. Jain N, Odenike O. Emerging role of the histone deacetylase inhibitor ro-midepsin in hematologic malignancies. Expert Opin Pharmacother 2010; 11:3073-84.
20. Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of ro-midepsin in patients with cutaneous T-cell lymphoma and relapsed pe-ripheral T-cell lymphoma. Clin Cancer Res 2009;15:1496-503.
21. Product information. Istodax (romidepsin). Summit, NJ: Celgene Corpo-ration, September 2011.
22. Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148:256-67.
23. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacety-lase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
24. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2: 325-32.
25. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicen-ter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-91.
26. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-15.
27. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoy-lanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lym-phoma (CTCL). Blood 2007;109:31-9.
28. Bunn PA, Foon KA, Ihde DC, et al. Recombinant leukocyte A interfer-on: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101:484-7.
29. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
30. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lym-phoma. Hematol Oncol Clin North Am 1995;9:1089-107.
31. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109:1799-803.
32. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lym-phoma. J Clin Oncol 2001;19:376-88.
33. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003;16:337-46.
34. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal pho-tochemotherapy. J Am Acad Dermatol 1996;35:935-45.
35. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104:2437-41.
36. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term out-come. Ann Oncol 2010;21:860-3.
37. Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007;92:686-9.
38. Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or re-fractory mycosis fungoides or Sézary syndrome. Arch Dermatol 2008;144: 727-33.
39. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of peg-ylated liposomal doxorubicin in patients with cutaneous T-cell lym-phoma. Cancer 2003;98:993-1001.
40. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tol-erated dose of pralatrexate in patients with relapsed or refractory cuta-neous T-cell lymphoma (abstract) Blood 2012;119(18):4115-22.
41. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome in-hibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-7.
42. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368-76.
43. Lansigan F, Foss FM. Current and emerging treatment strategies for cuta-neous T-cell lymphoma. Drugs 2010;70:273-86.
44. Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell trans-plantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28: 4492-9.
45. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase in-hibitors for cancer therapy. Cancer J 2007;13:30-9.
46. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. V.1.2012. www.nccn.org (accessed 2012 Jan 20).
47. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-73.
48. Hussar DA, Christian ME. New drugs: pitavastatin calcium, vigabatrin, and romidepsin. J Am Pharm Assoc (2003) 2010;50:548-51.
49. Zain J, O'Connor OA. Targeting histone deacetylases in the treatment of B-and T-cell malignancies. Invest New Drugs 2010;28(suppl 1):S58-78.
50. Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, John-stone RW. Characterisation of the novel apoptotic and therapeutic activi-ties of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008;7:1066-79.
51. Robey RW, Chakraborty AR, Basseville A, et al. Histone deacetylase in-hibitors: emerging mechanisms of resistance. Mol Pharm 2011;8:2021-31.
52. 2010 Redbook. Montvale, NJ: Thompson Medical Economics, 2010.
53. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in pa-tients with peripheral T-cell lymphoma. Blood 2011;117:5827-34.
54. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral t-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6.